AI news impact · China A-shares
Chongqing Lummy Pharmaceutical Co., Ltd. Class A (300006) news impact
On 2026-11-15 Wave Radar's AI rated the news on Chongqing Lummy Pharmaceutical Co., Ltd. Class A as neutral (impact score 0%).
Laibao Hi-Tech only appeared in statistical rankings tracking changes in margin trading balances with no material corporate news.
- Direction
- Neutral
- Impact score
- 0%
- Confidence
- 60%
- Headlines read
- 3
- Date
- 2026-11-15
AI assessment
Routine margin financing tracking without fundamental catalysts presents a neutral impact on share performance.
Sector impact
No noticeable impact on the electronic components or display materials sector.
Headlines the AI read
- 【数据揭秘】融资客看好个股一览 AkShare/证券时报网 · 2026-11-13
- 创业板公司融资余额减少15.81亿元,12股遭减仓超10% AkShare/证券时报网 · 2026-11-13
- 创业板股融资余额增幅榜(附股) AkShare/证券时报网 · 2026-11-10
Rating history
One rating per trading day the stock was covered.
More on Chongqing Lummy Pharmaceutical Co., Ltd. Class A
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.